Onclive Team

Dr. Stephen D. Nimer Honored with Endowed Chair

December 2nd 2019

The director of Sylvester Comprehensive Cancer Center is named the first holder of the Oscar de la Renta Endowed Chair in Cancer Research.

Symposium on Transforming Cancer Care in Hudson County Set for December 3 at Hackensack Meridian Health Palisades Medical Center

November 19th 2019

Cancer Surgeon Ashwani Rajput Named Director of the Johns Hopkins Kimmel Cancer Center for the National Capital Region

November 14th 2019

Ashwani Rajput, MD, a cancer surgeon and researcher with a special interest in health care disparities, has been appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, DC, region.

Association of Community Cancer Centers Honors Ethan Basch, MD, MSc, With Clinical Research Award

November 14th 2019

The Association of Community Cancer Centers (ACCC) 2019 Clinical Research Award was presented to Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program, and Professor, Hematology and Oncology, UNC, Lineberger Comprehensive Cancer Center. The award was presented during the ACCC 36th National Oncology Conference in Orlando, Florida.

The Armamentarium of Biosimilars Becomes More Robust

November 14th 2019

The slate of biosimilars for cancer is growing, and with this expansion the potential for price competition has improved.

Association of Community Cancer Centers Presents Annual Achievement Award Posthumously to Arti Hurria, MD, FASCO

November 12th 2019

The 2019 ACCC Annual Achievement Award was presented posthumously to Arti Hurria, MD, FASCO, City of Hope.

Association of Community Cancer Centers Presents David King Community Clinical Scientist Award to Paul D. Hansen, MD, FACS

November 8th 2019

The ACCC David King Community Clinical Scientist Award was awarded to Paul D. Hansen, MD, FACS, a pioneering leader in research on minimally invasive approaches to major liver and pancreas surgery and the promise these techniques hold for improving the quality of care, the patient experience, and potentially reducing healthcare costs.

Association of Community Cancer Centers Honors Seven Cancer Programs with Innovator Awards at 36th National Oncology Conference

November 5th 2019

The Association of Community Cancer Centers honored the recipients of 2019 ACCC Innovator Awards at the ACCC 36th National Oncology Conference in Orlando, Florida, where this year’s honorees shared innovative strategies and lessons learned from their own experience to enable others to model and scale similar initiatives.

ASCO Survey: E-Cigarettes Are Widely Misperceived as Harmless Among Young Adults

October 19th 2019

Findings from a national survey show that vaping is not only more common but also more favorably perceived among younger age groups than older adults.

City of Hope Is Enrolling Patients in First of its Kind Clinical Trial for Patients With Brain Tumors

October 10th 2019

The trial, which received a $4.1 million in grants from the National Institutes of Health and Gateway for Cancer Research, combines City of Hope’s unique CAR T cell therapy with immune checkpoint inhibitors.

Nivolumab/Tivozanib Combo Shows Promise in mRCC

October 8th 2019

Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.

Trametinib Emerges as New Standard Option for Recurrent, Low-Grade Ovarian Cancer

October 4th 2019

Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.

Entrectinib Delivers Durable Responses in ROS1+, NTRK+ Lung Cancer

October 3rd 2019

Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.

Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC

October 1st 2019

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer

September 30th 2019

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers

September 29th 2019

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer

September 29th 2019

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Trilaciclib Delivers "Unexpected" Survival Boost in TNBC

September 29th 2019

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer

September 28th 2019

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Cediranib/Olaparib Combo Shows Promise in Platinum-Resistant Ovarian Cancer

September 28th 2019

The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.